News
Posted on August 14, 2026
SCOTTSDALE, Ariz. — Less than 30 minutes per day of moderate to vigorous exercise may be sufficient to mitigate most cardiovascular risk related to physical inactivity, a speaker reported. At the American Society for Preventive Cardiology Congress on CVD Prevention, Paul D. Thompson, MD, emeritus chief of cardiology at Hartford Hospital and emeritus professor of medicine at University of Connecticut, discussed how much and what type of physical activity is needed to impact CV health. “Physical activity and exercise are used interchangeably. Physical activity is referred to as any bodily
Posted on August 13, 2026
SCOTTSDALE, Ariz. — Criticism of the 2026 American Heart Association/American College of Cardiology/Multisociety Guideline on the Management of Dyslipidemia abounds on social media. A speaker at the American Society for Preventive Cardiology Congress on CVD Prevention decided to take all of it on at once. In the guise of social media critics, Ann Marie Navar, MD, PhD, FAHA, FACC, FASPC, associate professor of medicine in the division of cardiology at UT Southwestern Medical Center, went through the common critiques of the guideline on social media, and then as herself, she rebutted them.
Posted on August 12, 2026
Healio LIVE and Healio AI announced a partnership that will increase Healio AI’s access to educational programming, strengthening the HIPAA-compliant platform’s knowledge base, according to a press release. The collaboration between Healio LIVE, which organizes live CME conferences, and Healio AI, which generates evidence-based responses to clinical questions, will provide relevant, critical and actionable insights to practicing clinicians and healthcare professionals (HCPs), according to the release. “With this partnership, Healio AI is bridging the gap between the latest clinical information
Posted on August 12, 2026
The FDA has expanded a safety alert warning consumers to avoid certain botanical weight loss supplements that contain toxic yellow oleander. Analysis showed three additional online products labeled as tejocote (Crataegus mexicana) root or Brazil seed instead contained yellow oleander (Thevetia peruviana) — a toxic plant native to Mexico and Central America. According to the FDA, these products can cause neurologic, gastrointestinal and cardiovascular adverse events that could be severe or fatal. The agency advises consumers to stop using and dispose of these products. Those who have used any of
Posted on August 12, 2026
Polyendocrine metabolic ovarian syndrome was associated with increased risk for atherosclerotic cardiovascular disease events and the association was only partially mediated by the presence of baseline comorbidities, researchers reported. Polyendocrine metabolic ovarian syndrome (PMOS), the new proposed name for polycystic ovary syndrome (PCOS), may be an independent predictor of ASCVD events, including coronary artery disease, cerebrovascular disease and peripheral artery disease, according to data published in The Lancet Obstetrics, Gynaecology, & Women’s Health. “Women with
Posted on August 12, 2026
SCOTTSDALE, Ariz. — Contrary to guidelines, one in three eligible patients with new-onset diabetes do not receive a prescription for statin therapy within 1 year of diagnosis, a speaker reported. Many patients with new-onset diabetes aged 40 to 75 years who may benefit from statin therapy do not receive it within 1 year, and among those who do, prescription may take months after initial diagnosis, according to study findings presented at the American Society for Preventive Cardiology Congress on CVD Prevention. “Diabetes increases [atherosclerotic] CVD risk by fourfold, and statins
Posted on August 12, 2026
GLP-1 receptor agonists are best known for treating type 2 diabetes and obesity, yet a growing body of evidence suggests their benefits may extend well beyond metabolic disease to dermatologic indications. “GLP-1s are the surprise anti-inflammatory that no one saw coming,” Mona Shahriari, MD, FAAD, associate clinical professor of dermatology at Yale University School of Medicine, told Healio. “They do much more than help with weight loss. They also reduce systemic inflammation.” Interest in GLP-1s’ dermatologic potential accelerated this year after the landmark TOGETHER-PsO trial showed that
Posted on August 12, 2026
Patients with diabetes, especially type 1 diabetes or insulin-dependent type 2 diabetes, need regular access to care, and in 2026, that has become challenging for many. Changes to Medicaid caused many patients to lose their insurance coverage, rising costs of goods such as food and gasoline have led some patients to reduce their spending on healthcare, and crackdowns related to immigration status have led some patients to stop coming to public places such as doctors’ offices. Healio | Endocrine Today Editorial Board Member Anne L. Peters, MD, professor of medicine at Keck School of Medicine of
Posted on August 12, 2026
In healthy young adults with normal spirometry, e-cigarette users and conventional cigarette smokers had similar poorer exercise capacity and vascular function vs. never vapers/smokers, according to findings published in ERJ Open Research. “This work is the first of its kind to identify reduced vascular function, ventilation efficiency and exercise capacity in people who vape and never smoked,” Azmy Faisal, PhD, senior lecturer of cardiorespiratory physiology at Manchester Metropolitan University and principal investigator of the study, told Healio. “The consequences of this finding are
Posted on August 11, 2026
Type 2 diabetes may substantially increase and worsen menopause symptoms in South Korean women, according to a study published in Menopause. “These findings not only highlight the need to recognize and address menopause symptoms in women with diabetes but also underscore the menopause transition as an important opportunity to identify and manage cardiovascular risk factors in all women,” Stephanie S. Faubion, MD, MBA, medical director of The Menopause Society, said in a press release. The research also builds upon current literature on associations between cardiovascular health and menopause,
Posted on August 11, 2026
Primary prevention of heart disease may be improved with the use of waist circumference or waist-to-height ratio rather than BMI to guide cardiovascular disease risk assessment, researchers reported. Many people with otherwise normal BMI but more central adiposity may experience increased risk for CV events. Conversely, those with obesity based on their BMI but lower central adiposity may have lower CV risk compared with those with obesity and higher central adiposity, according to data published in the Journal of the American College of Cardiology. “It is becoming more recognized that
Posted on August 11, 2026
SCOTTSDALE, Ariz. — Certain lipid parameters and biomarkers are better predictors of heart disease in women than LDL cholesterol level, a speaker said at the American Society for Preventive Cardiology Congress on CVD Prevention. The insight was part of the 2026 Nanette Wenger Award Lecture delivered by Samia Mora, MD, MHS, director of the Center for Lipid Metabolomics at Brigham and Women’s Hospital and professor of medicine at Harvard Medical School. The award, named after Healio | Cardiology Today Editorial Board Member Nanette Wenger, MD, who pioneered research on sex-specific CVD risk, is
Posted on August 11, 2026
Only about one in five patients with chronic kidney disease met the 2021 Kidney Disease: Improving Global Outcomes systolic blood pressure target, according to study data published in the Journal of the American Society of Nephrology. The 2021 KDIGO guideline on BP recommends a systolic BP target of less than 120 mm Hg for patients with CKD — a target lower than other BP guidelines at the time, according to Hyeok-Hee Lee, MD, PhD, a postdoctoral research fellow at Harvard Medical School. “The SPRINT trial showed that targeting systolic BP under 120 mm Hg led to a lower risk of CVD than
Posted on August 10, 2026
The risk for premature death from CVD occurring from one or more complicated pregnancies may widely vary, new research in European Heart Journal shows. “Cardiovascular disease in women is underrecognized and undertreated and, as such, pregnancy complications have been proposed as a way to identify at-risk women,” Aditi Singh, a PhD candidate at University of Bergen in Norway, said in a press release. “Our earlier work found that a woman’s risk of premature cardiovascular mortality increases with the number of complicated pregnancies. However, many studies and guidelines still only ask whether
Posted on August 10, 2026
Physical activity was linked to reduced risk for stroke and all-cause mortality to a similar extent in people with and without atrial fibrillation, researchers reported. The health benefits of exercise were observed even at low levels of physical activity compared with inactivity and showed potential longevity benefits as well, according to study findings published in the Journal of the American Heart Association. “The results from our study indicate that physical activity was associated with a reduced risk of stroke and death in individuals with and without atrial fibrillation. So,
Posted on August 10, 2026
SCOTTSDALE, Ariz. — Incidental qualitative coronary artery calcium findings can identify which patients with psoriatic disease need their cardiovascular risk managed, researchers reported. In a presentation that won the award for best oral abstract on the second day of the American Society for Preventive Cardiology Congress on CVD Prevention, Brooke Bartley, MD, dermatology resident at University of Texas Medical Branch and UT Southwestern Medical Center, discussed findings from the STRATIFY-PsD project. “This is a joint initiative between cardiology and dermatology, and it explores the
Posted on August 7, 2026
Xylazine scheduling may have contributed to a substantial increase in medetomidine in the U.S. illicit drug supply, a new research paper suggests. “Although this study is the first to examine this for xylazine/medetomidine, these ‘iron law of prohibition’ patterns are not new,” David T. Zhu, an MD/PhD candidate at Virginia Commonwealth University, told Healio. “Currently, many state policymakers and legislators are still debating whether to schedule xylazine and medetomidine — our findings provide a cautionary tale against these supply-side drug control policies.” In recent years, there has
Posted on August 7, 2026
SCOTTSDALE, Ariz. — The prevalence of genetic high cholesterol is estimated to be approximately sevenfold higher in the South Asian population compared with previous estimations in the global general population, a speaker reported. Compared with South Asian individuals without heterozygous familial hypercholesterolemia, those with heterozygous FH (HeFH) may have an up to twofold greater risk for major adverse CV events, premature atherosclerotic CVD, CV death and all-cause death, according to a presentation. At the American Society for Preventive Cardiology Congress on CVD Prevention,
Posted on August 7, 2026
Kidney failure risk may impact treatment effectiveness of SGLT2 inhibitors vs. GLP-1 drugs for veterans with type 2 diabetes, according to study data published in the Journal of the American Society of Nephrology. Currently, no randomized controlled trials have compared the effectiveness of SGLT2 inhibitors vs. non-exendin GLP-1 receptor agonists, according to Srinivasan Beddhu, MD, scientific director at the Cardiovascular, Renal and Metabolism Center, Sydney E. Hartsell, MD, MPH, physician scientist in the division of nephrology and hypertension, both at University of Utah Health, and
Posted on August 7, 2026
The number of adults with elevated LDL increased from 2.5 billion in 1990 to 4.6 billion in 2023, with 6% of all global deaths attributable to high LDL in 2023, according to study findings published in JAMA. Although age-standardized deaths and disability-adjusted life-years associated with elevated LDL decreased since 1990, the LDL burden shifted and now affects more middle-income countries, researchers reported. “LDL is one of the most established, modifiable drivers of ASCVD, yet most data track population lipid trends in isolation from actual outcomes,” Christian Razo, PhD, acting assistant
Stay updated
Sign up to receive news and updates on our iniciatives, content and events.